|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...7891011121314151617...110111» |
- ||| Trial completion, Trial primary completion date: PerClot Compared to Usual Care in Gynaecology Procedures (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=90, Completed, Sponsor: CryoLife Europa
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017
- | cisplatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: DEPICT: Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - Aug 31, 2017
P1/2, N=22, Active, not recruiting, Sponsor: Barts & The London NHS Trust
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017 Recruiting --> Active, not recruiting | N=44 --> 22 | Trial primary completion date: Jul 2013 --> Apr 2018
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Aug 30, 2017
P1, N=24, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=44 --> 22 | Trial primary completion date: Jul 2013 --> Apr 2018 Active, not recruiting --> Completed
- | progesterone / Generic mfg., progesterone / Generic mfg.
Trial initiation date, Trial primary completion date: Cerclage for Twins With Short Cervix (clinicaltrials.gov) - Aug 30, 2017
P2/3, N=152, Not yet recruiting, Sponsor: Mednax Center for Research, Education and Quality
Active, not recruiting --> Completed Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: Jul 2021 --> Oct 2021
- | triptorelin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG (clinicaltrials.gov) - Aug 29, 2017
P4, N=93, Completed, Sponsor: HaEmek Medical Center, Israel
Initiation date: Jul 2017 --> Oct 2017 | Trial primary completion date: Jul 2021 --> Oct 2021 Recruiting --> Completed | N=200 --> 93 | Trial primary completion date: Oct 2016 --> Jul 2017
- | Trial primary completion date: FemCure: Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women (clinicaltrials.gov) - Aug 29, 2017
P=N/A, N=400, Recruiting, Sponsor: Maastricht University Medical Center
Recruiting --> Completed | N=200 --> 93 | Trial primary completion date: Oct 2016 --> Jul 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- | Trial completion: Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. (clinicaltrials.gov) - Aug 29, 2017
P=N/A, N=16, Completed, Sponsor: Mauna Kea Technologies
Trial primary completion date: Mar 2017 --> Dec 2017 Active, not recruiting --> Completed
- ||| Bravelle (urofollitropin) / Ferring
Trial completion, Enrollment change, Trial primary completion date: Study of the Cleavage of the Egg in Relation to the Stimulation Treatment (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=356, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=272 --> 356 | Trial primary completion date: Aug 2016 --> Dec 2015
- ||| Menopur (menotropin) / Ferring
Trial completion, Trial primary completion date: An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=738, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed | N=272 --> 356 | Trial primary completion date: Aug 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2016
- | Trial completion: Serum Caspase 3, Annexin a2 and Soluble Fas Levels and Endometriosis (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=90, Completed, Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Feb 2016 Recruiting --> Completed
- | Trial completion: Serum Kisspeptin Levels in Infertile Women (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=90, Completed, Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Recruiting --> Completed Recruiting --> Completed
- | cisplatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: DEPICT: Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - Aug 28, 2017
P1/2, N=22, Active, not recruiting, Sponsor: Queen Mary University of London
Recruiting --> Completed Recruiting --> Active, not recruiting | N=44 --> 22 | Trial primary completion date: Jul 2015 --> Apr 2016
- | Phase classification, Trial termination, Trial primary completion date: Preventing Health Damaging Behaviors in Male and Female Army Recruits (clinicaltrials.gov) - Aug 25, 2017
P=N/A, N=933, Terminated, Sponsor: United States Department of Defense
Recruiting --> Active, not recruiting | N=44 --> 22 | Trial primary completion date: Jul 2015 --> Apr 2016 Phase classification: P2 --> P=N/A | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Mar 2013; Due to lack of continue funding
- | cefixime / Generic mfg., azithromycin / Generic mfg.
Trial completion: Cefixime / Azithromycin pK Study (clinicaltrials.gov) - Aug 25, 2017
P1, N=10, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P2 --> P=N/A | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Mar 2013; Due to lack of continue funding Active, not recruiting --> Completed
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=27, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- | Trial completion, Enrollment change, Trial primary completion date, IO biomarker, Surgery, Metastases: Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes (clinicaltrials.gov) - Aug 24, 2017
P=N/A, N=159, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Active, not recruiting --> Completed | N=286 --> 159 | Trial primary completion date: Jan 2100 --> Jul 2016
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
Trial primary completion date, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=16, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | N=286 --> 159 | Trial primary completion date: Jan 2100 --> Jul 2016 Trial primary completion date: Dec 2014 --> Jul 2015
- epacadostat (INCB024360) / Incyte
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=2, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2014 --> Jul 2015 Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015
- | topotecan / Generic mfg., acetylcysteine solution / Generic mfg.
Biomarker, Trial primary completion date, Tumor microenvironment: Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 24, 2017
P2, N=1, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015 Trial primary completion date: Oct 2019 --> Jun 2017
- | Trial completion, Trial primary completion date: Autologous Mitochondrial Transfer in ICSI to Improve Oocyte and Embryo Quality in IVF Patients. Pilot Study (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=59, Completed, Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Trial primary completion date: Oct 2019 --> Jun 2017 Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Mar 2017
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Prognostic Biomarkers in Patients With Endometrial Cancer (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=2824, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Mar 2017 Not yet recruiting --> Completed | Initiation date: Jan 2100 --> Sep 2010 | Trial primary completion date: Jan 2100 --> May 2014
- | Trial completion, Trial primary completion date: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=120, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Completed | Initiation date: Jan 2100 --> Sep 2010 | Trial primary completion date: Jan 2100 --> May 2014 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2017
- | Trial primary completion date: SeTPAT: Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=150, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2017 Trial primary completion date: Jul 2017 --> Dec 2017
- | Enrollment change, Trial withdrawal, Trial primary completion date: Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=0, Withdrawn, Sponsor: KK Women's and Children's Hospital
Trial primary completion date: Jul 2017 --> Dec 2017 N=48 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Sep 2016 --> Jun 2016
- | Trial completion, Trial primary completion date, Surgery: OVHIPEC: Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer (clinicaltrials.gov) - Aug 22, 2017
P3, N=242, Completed, Sponsor: The Netherlands Cancer Institute
N=48 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Sep 2016 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Aug 2017
- | Trial primary completion date, HEOR: Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=14, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Aug 2017 Trial primary completion date: Nov 2017 --> Apr 2018
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Aug 22, 2017
P1, N=9, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Nov 2017 --> Apr 2018 Trial primary completion date: Sep 2017 --> Aug 2018
- ||||| Zybrestat (fosbretabulin) / Oncotelic
Enrollment closed: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Aug 22, 2017
P2/3, N=436, Active, not recruiting, Sponsor: Mateon Therapeutics
Trial primary completion date: Sep 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- | lifastuzumab vedotin (DNIB0600A) / Roche
Trial termination: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Aug 21, 2017
P2, N=95, Terminated, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria.
- |||| Elonva (corifollitropin alfa) / Organon
Trial completion, Preclinical, Trial primary completion date: Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients (clinicaltrials.gov) - Aug 21, 2017
P4, N=400, Completed, Sponsor: Vietnam National University
Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria. Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- | Phase classification: A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (clinicaltrials.gov) - Aug 21, 2017
P=N/A, N=1208, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016 Phase classification: P1 --> P=N/A
- | Enrollment open: STI Screening as a Combined HIV Prevention Platform for MSM in Peru (clinicaltrials.gov) - Aug 21, 2017
P=N/A, N=150, Recruiting, Sponsor: University of California, Los Angeles
Phase classification: P1 --> P=N/A Not yet recruiting --> Recruiting
- | Trial completion: Evaluation of Enhanced Syphilis Screening Among HIV-positive Men (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=3131, Completed, Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Trial initiation date, Trial primary completion date: Clinical Pregnancy Rate After Removal of Unsuspected Polyps (clinicaltrials.gov) - Aug 18, 2017
P3, N=200, Not yet recruiting, Sponsor: Karachi Medical and Dental College
Recruiting --> Completed Initiation date: May 2016 --> Dec 2017 | Trial primary completion date: Sep 2017 --> Dec 2019
- | progesterone / Generic mfg.
Biomarker, Trial completion: Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells. (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=60, Completed, Sponsor: Kayseri Education and Research Hospital
Initiation date: May 2016 --> Dec 2017 | Trial primary completion date: Sep 2017 --> Dec 2019 Not yet recruiting --> Completed
- polyvalent vaccine-KLH conjugate / MabVax, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, IO biomarker: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Completed Trial primary completion date: Oct 2017 --> Oct 2018
- | Trial primary completion date, BRCA Biomarker: Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=1905, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Jul 2017 --> Jul 2018
- cyclophosphamide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: EMR 62206-016: Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. (clinicaltrials.gov) - Aug 18, 2017
P2, N=0, Withdrawn, Sponsor: EMD Serono
Trial primary completion date: Jul 2017 --> Jul 2018 N=140 --> 0 | Terminated --> Withdrawn | Trial primary completion date: May 2007 --> May 2008
- | indomethacin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: PIFA: Phase I Platinum Based Chemotherapy Plus Indomethacin (clinicaltrials.gov) - Aug 18, 2017
P1, N=13, Completed, Sponsor: UMC Utrecht
N=140 --> 0 | Terminated --> Withdrawn | Trial primary completion date: May 2007 --> May 2008 Recruiting --> Completed | N=18 --> 13 | Trial primary completion date: Dec 2018 --> Aug 2017
- | IDC-G305 / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Aug 17, 2017
P1, N=13, Completed, Sponsor: Immune Design
Recruiting --> Completed | N=18 --> 13 | Trial primary completion date: Dec 2018 --> Aug 2017 Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Nov 2014 --> Dec 2016
- | Enrollment closed, Enrollment change, Trial primary completion date: Fermented Wheat Germ Extract in Women With Ovarian Cancer (clinicaltrials.gov) - Aug 17, 2017
P=N/A, N=3, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Nov 2014 --> Dec 2016 Recruiting --> Active, not recruiting | N=20 --> 3 | Trial primary completion date: Dec 2018 --> Aug 2017
- Enrollment change, Trial termination: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Aug 16, 2017
P=N/A, N=1336, Terminated, Sponsor: Gen-Probe, Incorporated
Recruiting --> Active, not recruiting | N=20 --> 3 | Trial primary completion date: Dec 2018 --> Aug 2017 N=2100 --> 1336 | Active, not recruiting --> Terminated; Corporate decision to spend money on other development programs.
- | Trial completion, Metastases: TIL Therapy for Metastatic Ovarian Cancer (clinicaltrials.gov) - Aug 16, 2017
P1, N=6, Completed, Sponsor: Inge Marie Svane
N=2100 --> 1336 | Active, not recruiting --> Terminated; Corporate decision to spend money on other development programs. Active, not recruiting --> Completed
- | Trial initiation date, Trial primary completion date: OB-PCO: The Effect of Obesity on Endometrium in PCOS (clinicaltrials.gov) - Aug 11, 2017
P=N/A, N=100, Completed, Sponsor: Assiut University
Active, not recruiting --> Completed Initiation date: Jan 2015 --> Feb 2016 | Trial primary completion date: Nov 2015 --> Dec 2016
- | oral amphotericin B (MAT2203) / Matinas
Trial completion, Enrollment change: Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) (clinicaltrials.gov) - Aug 11, 2017
P2, N=137, Completed, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Initiation date: Jan 2015 --> Feb 2016 | Trial primary completion date: Nov 2015 --> Dec 2016 Recruiting --> Completed | N=75 --> 137
- | Nexplanon (etonogestrel implant) / Organon
Trial completion, Trial initiation date, Trial primary completion date: Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis (clinicaltrials.gov) - Aug 11, 2017
P4, N=100, Completed, Sponsor: University of Campinas, Brazil
Recruiting --> Completed | N=75 --> 137 Not yet recruiting --> Completed | Initiation date: Jul 2015 --> May 2016 | Trial primary completion date: Jul 2015 --> Aug 2017
- || adavosertib (AZD1775) / AstraZeneca
Enrollment change, Monotherapy, Metastases: Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. (clinicaltrials.gov) - Aug 10, 2017
P1, N=78, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Completed | Initiation date: Jul 2015 --> May 2016 | Trial primary completion date: Jul 2015 --> Aug 2017 N=98 --> 78
- | CTH522 / Statens Serum Institut, Imperial College London
Trial completion: Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years (clinicaltrials.gov) - Aug 10, 2017
P1, N=35, Completed, Sponsor: Statens Serum Institut
N=98 --> 78 Recruiting --> Completed
- | Trial completion, Enrollment change: Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER) (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=495, Completed, Sponsor: Hopital Foch
Recruiting --> Completed Recruiting --> Completed | N=800 --> 495
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 9, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=800 --> 495 Trial primary completion date: Jan 2010 --> May 2004